AzTrials
AzTrials

COVID-19Phase 2NCT06742281

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

A Phase 2 study testing CVXGA (CVXGA50) and COMIRNATY® in people with COVID-19, run by CyanVac LLC at 55 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
Conditions the study is for
COVID-19
What is being tested?
CVXGA (CVXGA50) and COMIRNATY®
Could I receive a placebo?
No, everyone receives an active treatment
How many people
432 participants
Where
55 sitesUnited States
Study dates
5 Dec 2024to 15 Jun 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Is an adult ≥18 years of age at time of screening.
  • Has completed any WHO/FDA-authorized or approved primary COVID-19 vaccination series.
  • Has received last COVID-19 vaccine no less than 6 months prior to study enrollment (study vaccination).
  • If a female of childbearing potential who is sexually active, agrees to use an adequate method of birth control from Screening through 90 days after last study vaccination, and has used an adequate birth control method for at least 30 days prior to Screening.
  • Female of childbearing potential is defined as post onset menarche and pre-menopausal person capable of becoming pregnant. This does not include females who meet any of the following conditions: a) menopausal >2 years; b) tubal ligation >1 year; c) bilateral salpingo-oophorectomy; or d) hysterectomy.
  • Adequate contraception is defined as a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label. Examples include: oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; the female participant has exclusively female sexual partners; partner is sterile or otherwise unable to produce sperm (information on the person's sterility can come from the site personnel's review of the participant's medical records or interview with the participant regarding her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); or male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
Show all 10Show fewer
  • Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination).
  • Agrees to not participate in any other SARS-CoV-2 infection prevention trial (vaccine, drug, biologic, or pre-exposure prophylaxis [PrEP]) during participation in the study.
  • Willing and able to provide informed consent prior to initiation of study procedures.
  • Is available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study.

Who cannot join

  • Has an acute illness, as determined by the site investigator, within 72 hours prior to Screening or study vaccination.
  • An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol.)
  • Has had a positive COVID-19 test within the 90 days prior to Screening or study vaccination.
  • Current or planned participation in any other interventional clinical trial.
  • Prior receipt of a PIV5-based vaccine (e.g., CVXGA1, CVXGA35, or BLB201 [an RSV vaccine being developed by CyanVac/Blue Lake Biotechnology]).
  • Participation in research involving any investigational product within 45 days prior to Screening or study vaccination.
Show all 35Show fewer
  • Receipt of any approved or authorized products intended to prevent SARS-CoV-2 infection within 6 months prior to Screening (complete list provided in the pharmacy manual).
  • Receipt or anticipated receipt of, within 7 days prior through 31 days after study vaccination, any intranasal medication including FDA approved prescription or over-the-counter products or non-FDA approved alternative medicine products (e.g., intranasal Fluticasone {commonly used intranasal products that would be used, which is not herbal/naturopathic}, Ayurvedic oil or other naturopathic substances).
  • Anticipated use of nasal irrigation (e.g., Neti PotTM) from Screening through 31 days after study vaccination.
  • Receipt of blood products or immunoglobulins within 60 days prior to Screening or study vaccination.
  • Received influenza vaccination within 14 days prior to Screening or study vaccination, or any other vaccine within 30 days prior to Screening or study vaccination.
  • Any significant or uncontrolled autoimmune, immunodeficiency disease/condition, or autoinflammatory disorder (e.g. untreated or advanced human immunodeficiency virus [HIV] infection with CD4 counts <200 cells/mm3, history of acquired immunodeficiency syndrome [AIDS] defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV).
  • Unstable illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to Screening or study vaccination.
  • History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any medical condition that, in the opinion of the investigator, increases risk of myocarditis or pericarditis.
  • Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes:
  • B-cell therapies within the 6 months prior to Screening or study vaccination.
  • Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to Screening or study vaccination.
  • Monoclonal antibodies that may suppress aspects of immune response (e.g., Dupixent) within the 6 months prior to Screening or study vaccination.
  • Other medications in this category, including but not limited to high-dose inhaled corticosteroids (>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to Screening or study vaccination.
  • Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination.
  • Individuals who have close contact or high-risk contact with persons who may be severely immunocompromised, within 14 days following the study vaccination. High-risk contacts include but are not limited to:
  • Residents of nursing homes or rehabilitation facilities
  • Persons of any age with any significant immunodeficiency disease (e.g., untreated or advanced HIV, history of AIDS, or clinical manifestations of HIV)
  • Persons of any age being administered immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs
  • Persons of any age with a known history of significant airway reactivity to viruses (e.g., severe asthma, advanced chronic obstructive disease, or cystic fibrosis)
  • Persons of any age immunosuppressed due to cancer or undergoing active treatment for cancer
  • Women who are pregnant, breastfeeding, or who plan to become pregnant during the study; and
  • Infants age ≤6 months.
  • Known contraindication to IM injection (e.g., bleeding diathesis, acquired coagulopathy) or to intranasal administration (e.g., severe nasal obstruction, significant chronic rhinitis, nasal septal defect causing significant breathing problems, unrepaired cleft palate, nasal polyps, or other nasal abnormality that, in the opinion of the investigator, may affect vaccine administration).
  • History of significant/severe wheezing or respiratory symptoms resulting in hospitalization or known bronchial hyperreactivity to viruses.
  • History of severe adverse reaction to vaccination in the past, including to COVID-19 vaccination.
  • Any known allergies to components contained in CVXGA or COMIRNATY (including polyethylene glycol [PEG] allergies), or latex.
  • Women who are pregnant, breastfeeding, or who plan to become pregnant during the study.
  • Any other condition that, in the opinion of the site investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
  • Study team member or first-degree relative of any study team member (inclusive of CyanVac and site personnel involved in the study).

Trial locations and contacts

55 sites in 1 country.

55 sites in 1 country

United States55 sites

  • Velocity Clinical Research, Anderson

    Anderson, South Carolina, 29621

  • Pinnacle Research Group, LLC

    Anniston, Alabama, 36207

  • Avacare

    Austin, Texas, 78705

  • Tekton Research, LLC

    Austin, Texas, 78745

  • Velocity Clinical Research, Austin

    Austin, Texas, 78759

  • Velocity Clinical Research, Cleveland

    Beachwood, Ohio, 44122

  • Velocity Clinical Research, Binghamton

    Binghamton, New York, 13905

  • Pan American Clinical Research, LLC

    Brownsville, Texas, 78520

  • Velocity Clinical Research, Chula Vista

    Chula Vista, California, 91911

  • Velocity Clinical Research, Mt. Auburn

    Cincinnati, Ohio, 45219

  • Velocity Clinical Research, Springdale

    Cincinnati, Ohio, 45246

  • Velocity Clinical Research, Covington

    Covington, Louisiana, 70433

  • Avacare

    Fort Worth, Texas, 76135

  • Velocity Clinical Research Gaffney

    Gaffney, South Carolina, 29340

  • CBH Health

    Gaithersburg, Maryland, 20877

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida, 33009

  • Homestead Associates in Research, Inc

    Homestead, Florida, 33033

  • DM Clinical Research

    Houston, Texas, 77065

  • DM Clinical Research

    Houston, Texas, 77081

  • DM Clinical Research

    Jersey City, New Jersey, 07306

  • Velocity Clinical Research, San Diego

    La Mesa, California, 91942

  • Imax Clinical Trials

    La Palma, California, 90623

  • Velocity Clinical Research, Lafayette

    Lafayette, Louisiana, 70508

  • Lifeline Primary Care/Avacare

    Lilburn, Georgia, 30047

  • Velocity Clinical Research, Boise

    Meridian, Idaho, 83642

  • Velocity Clinical Research, New Orleans

    New Orleans, Louisiana, 70119

  • Velocity Clinical Research - Norfolk

    Norfolk, Nebraska, 68701

  • Biscayne Clinical Research

    North Miami Beach, Florida, 33169

  • Quality Clinical Research, Inc

    Omaha, Nebraska, 68114

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska, 68134

  • Headlands Research Orlando

    Orlando, Florida, 32819

  • Best Choice Medical and Research Service

    Pembroke Pines, Florida, 33024

  • DM Clinical Research

    Philadelphia, Pennsylvania, 19107

  • Velocity Clinical Research, Phoenix

    Phoenix, Arizona, 85006

  • Clinical Research Partners LLC

    Richmond, Virginia, 23226

  • Artemis Institute for Clinical Research

    Riverside, California, 92503

  • Clinical Innovations Inc. dba CITrials

    Riverside, California, 92506

  • Rochester Clinical Research

    Rochester, New York, 14609

  • Advanced Primary and Geriatric Care/Avacare

    Rockville, Maryland, 20850

  • Velocity Clinical Research, Rockville

    Rockville, Maryland, 20854

  • Avacare

    Sacramento, California, 95864

  • Avacare

    San Angelo, Texas, 76904

  • Tekton Research, LLC

    San Antonio, Texas, 78229

  • Velocity Clinical Research, Savannah

    Savannah, Georgia, 31406

  • Velocity Clinical Research, Sioux City

    Sioux City, Iowa, 51106

  • DM Clinical Research

    Southfield, Michigan, 48076

  • Clinical Research Atlanta

    Stockbridge, Georgia, 30281

  • Velocity Clinical Research, Suffolk

    Suffolk, Virginia, 23435

  • Forcare Clinical Research

    Tampa, Florida, 33613

  • Guardian Angel Research Center

    Tampa, Florida, 33614

  • Collaborative Neuroscience Research, LLC

    Torrance, California, 90504

  • Velocity Clinical Research, Washington DC

    Washington D.C., District of Columbia, 20016

  • Velocity Clinical Research, Salt Lake City

    West Jordan, Utah, 84088

  • Trial Management Associates, LLC

    Wilmington, North Carolina, 28403

  • Tekton Research, LLC

    Yukon, Oklahoma, 73099

Other trials in United States

About this study

Official title: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.

Read the detailed description

This is a double-blind, active comparator-controlled Phase 2b study to evaluate the efficacy, immunogenicity, and safety study in which eligible adult participants will be randomized 1:1 to receive CVXGA (CVXGA50) or COMIRNATY.

Number of Participants:

The proposed enrollment for this study is approximately 434 participants, that includes 16 participants enrolled in Sentinel Cohort 1 and Sentinel Cohort 2 (8 participants in each cohort).

Treatment Assignment:

Participants in Sentinel Cohort 1 and Sentinel Cohort 2 will be assigned to receive a single dose of CVXGA (CVXGA50) intranasally and will not receive an IM placebo.

All other participants in the study will be randomized 1:1 to receive a single dose of CVXGA (CVXGA50) intranasally (plus a single dose of IM placebo), or a single dose of IM COMIRNATY (plus a single dose of intranasal placebo).

Study visits: Participants will be asked to complete approximately 6-7 clinic visits, over a period of approximately 12 months duration per participant.

Conditions
COVID-19
Being tested
CVXGA (CVXGA50), COMIRNATY®
Keywords
COVID-19 intranasal vaccine
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CVXGA (CVXGA50)Biological

    CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.

  • COMIRNATY®Biological

    COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH [Mainz, Germany] and Pfizer Inc. [New York, NY]) will be used as the comparator vaccine for this study.

Study groups in NCT06742281
Study groupRoleWhat they receive
CVXGA (CVXGA50)ExperimentalCVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
Receives: Biological: CVXGA (CVXGA50)
COMIRNATY®Active comparatorCOMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH [Mainz, Germany] and Pfizer Inc. [New York, NY]) will be used as the comparator vaccine for this study.
Receives: Biological: COMIRNATY®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of participants with symptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula) to compare differences in relative vaccine efficacy.

    First occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 according to the case definition with onset at least 14 days post-vaccination through 12 months post-vaccination.

    Case definition: Virologically confirmed SARS-CoV-2 infection (by RT-PCR) with 1 or more of the following symptoms within ±7 days:

    • Fever or chills
    • Cough
    • Shortness of breath or difficulty breathing
    • Fatigue
    • Muscle or body aches
    • Headache
    • New loss of taste or smell
    • Sore throat
    • Congestion or runny nose
    • Nausea or vomiting
    • Diarrhea

    Measured: Day 14 to Day 366 post-vaccination.

Secondary outcomes (16)

  1. Time until first occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 for CVXGA (CVXGA50) compared to COMIRNATY to determine durability

    First occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 according to the case definition with onset at least 14 days post-vaccination through 12 months post-vaccination evaluated separately in 0-6- and 6-12- month time periods.

    Measured: Day 1 to Day 366 post-vaccination.

  2. Percentage of participants with asymptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY to determine relative efficacy.

    First occurrence of molecularly confirmed (RT-PCR -positive) asymptomatic COVID-19 from 14 days post-vaccination through 12 months post-vaccination.

    Measured: Day 14 to Day 366 post-vaccination.

  3. Percentage of participants with severe COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY to determine relative efficacy.

    First occurrence of molecularly confirmed (RT-PCR-positive) severe COVID-19 according to the case definition from 14 days post-vaccination through 12 months post-vaccination.

    Case definition: Virologically confirmed SARS-CoV-2 infection (by RT-PCR) with any of the following:

    • Clinical signs at rest indicative of severe systemic illness (respiratory rate ≥30 breaths per minute, heart rate ≥125 beats per minute, SpO2 ≤93% on room air or PaO2/FiO2 <300 mm Hg)
    • Respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation [ECMO])
    • Evidence of shock (systolic blood pressure [SBP] <90 mm Hg, diastolic blood pressure [DBP] <60 mm Hg, or requiring vasopressors)
    • Significant acute renal, hepatic, or neurologic dysfunction
    • Admission to an intensive care unit (ICU)
    • Death

    Measured: Day 14 to Day 366 post-vaccination.

  4. The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intranasal administration through 7 days post-vaccination.

    The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intranasal administration through 7 days post-vaccination.

    Measured: Time Frame: Day 1 to Day 7 post-vaccination.

  5. The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intramuscular (IM) administration through 7 days post-vaccination.

    The percentage of participants who experience any solicited local reactogenicity symptom pertaining to intramuscular (IM) administration through 7 days post-vaccination.

    Measured: Day 1 to Day 7 post-vaccination.

  6. The percentage of participants who experience any solicited systemic reactogenicity symptom through 7 days post-vaccination.

    The percentage of participants who experience any solicited systemic reactogenicity symptom through 7 days post-vaccination.

    Measured: Day 1 to Day 7 post-vaccination.

  7. The percentage of participants who experience any unsolicited adverse event (AE) through 30 days post-vaccination.

    The percentage of participants who experience any unsolicited adverse event (AE) through 30 days post-vaccination.

    Measured: Day 1 to Day 30 post-vaccination.

  8. The percentage of participants who experience the following events through 12 months post-vaccination: o serious adverse events (SAEs) o medically attended adverse events (MAAEs) o adverse events of special interest (AESIs)

    The percentage of participants who experience the following events through 12 months post-vaccination:

    • serious adverse events (SAEs)
    • medically attended adverse events (MAAEs)
    • adverse events of special interest (AESIs)

    Measured: Day 1 to Day 366 post-vaccination.

  9. The percentage of participants with any new or worsening clinically significant abnormal safety laboratory result (serum chemistries and hematology) through 7 days post-vaccination.

    The percentage of participants with any new or worsening clinically significant abnormal safety laboratory result (serum chemistries and hematology) through 7 days post-vaccination.

    Measured: Day 1 to Day 7 post-vaccination.

  10. Geometric mean titer (GMT) of SARS-CoV-2 specific neutralizing antibody (nAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    Geometric mean titer (GMT) of SARS-CoV-2 specific neutralizing antibody (nAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  11. Geometric mean fold rise (GMFR) of SARS-CoV-2 specific nAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    Geometric mean fold rise (GMFR) of SARS-CoV-2 specific nAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  12. GMT of anti-spike (S) protein-specific binding antibody (bAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    GMT of anti-spike (S) protein-specific binding antibody (bAb) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  13. GMFR of S protein-specific bAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    GMFR of S protein-specific bAb relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  14. GMT of S protein-specific IgA (nasal lining/saliva samples) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    GMT of S protein-specific IgA (nasal lining/saliva samples) at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  15. GMFR of S protein-specific IgA (nasal lining/saliva samples) relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    GMFR of S protein-specific IgA (nasal lining/saliva samples) relative to Day 1 at Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

  16. The percentage of subjects with increases in S-specific cytokine increases by cell type.

    Intracellular cytokine and cell surface marker staining at Day 1 and Days 31, 91, 181, and 366 post-vaccination.

    Measured: Day 1 to Day 366 post-vaccination.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2024
  2. Study start5 Dec 2024
  3. Primary completion15 Jun 2026
  4. Study completion15 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
432 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06742281
Sponsor's protocol ID
CVXGA-003
Other IDs
24-04-NGVx-002
Status last verified
Oct 2026
First submitted
17 Dec 2024
Last updated
13 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing CVXGA (CVXGA50) and COMIRNATY® in people with COVID-19, run by CyanVac LLC at 55 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 55 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of participants with symptomatic COVID-19 after boost with CVXGA (CVXGA50) compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula) to compare differences in relative vaccine efficacy. (time frame: Day 14 to Day 366 post-vaccination.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06742281.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in